School of Pharmacy, University of Eastern Finland, Yliopistonranta 1B, 70210 Kuopio, Finland.
Institute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, University of Turku, Kiinanmyllynkatu 10, 20520 Turku, Finland.
J Pharm Biomed Anal. 2018 Apr 15;152:165-172. doi: 10.1016/j.jpba.2018.01.034. Epub 2018 Jan 31.
An LC-MS/MS method was developed and validated to analyze simultaneously estrogens (estradiol, E2; estrone, E1), androgens (testosterone, T; androstenedione, A4; dehydroepiandrosterone, DHEA), progestagens (17a-hydroxypregnenolone, 17OHP5; 17a-hydroxyprogesterone, 17OHP4; progesterone, P4), glucocorticoids (cortisol, F; cortisone E; corticosterone, B; 11-deoxycortisol, S; 21-hydroxyprogesterone, 21OHP4), and mineralocorticoids (aldosterone, A) from 150 μl of human serum, plasma, or endometrium and endometriotic tissue homogenates. Samples spiked with isotope-labeled steroids as internal standards were extracted with toluene prior to LC-MS/MS analysis. The chromatographic separation of underivatized steroids was achieved on a biphenyl column with 0.2 mM NHF as the eluent additive and a water-methanol gradient to improve E2 and E1 ionization. Method validation was performed with human plasma samples, and analysis of certified E2, T, F, and P4 reference serums (BCR-576, ERM-DA346, ERM-DA192, ERM-DA347), as well as homogenates of endometrium and endometriotic tissue. A total of 27 steroids were included in the method development to ensure the specificity of the method. After validation, the method was found suitable for quantitative analysis of 11 steroids: E2 (6.7 pM-13 nM), E1 (1.3 pM-6.6 nM), T (3.3 pM-13 nM), A4 (13 pM-33 nM), 17OHP5 (32 pM-65 nM), 17OHP4 (33 pM-13 nM), F (33 pM-133 nM), E (13 pM-130 nM), B (33 pM-134 nM), S (13 pM-129 nM), and A (32 pM-32 nM). In addition, DHEA (333 pM-32 nM), P4 (13 pM-13 nM) and 21OHP4 (13 pM-13 nM) can be analyzed semiquantitatively.
建立并验证了一种 LC-MS/MS 方法,用于同时分析雌激素(雌二醇,E2;雌酮,E1)、雄激素(睾酮,T;雄烯二酮,A4;脱氢表雄酮,DHEA)、孕激素(17α-羟孕烯醇酮,17OHP5;17α-羟孕酮,17OHP4;孕酮,P4)、皮质类固醇(皮质醇,F;皮质酮,E;皮质酮,B;11-脱氧皮质醇,S;21-羟孕酮,21OHP4)和盐皮质激素(醛固酮,A),从 150 μl 人血清、血浆或子宫内膜和子宫内膜异位组织匀浆中提取。用甲苯提取加同位素标记类固醇内标物的样品,然后进行 LC-MS/MS 分析。未衍生类固醇的色谱分离在联苯柱上进行,以 0.2 mM NHF 为洗脱添加剂,水-甲醇梯度提高 E2 和 E1 的离子化效率。用人血浆样品进行方法验证,并分析了认证的 E2、T、F 和 P4 参考血清(BCR-576、ERM-DA346、ERM-DA192、ERM-DA347),以及子宫内膜和子宫内膜异位组织的匀浆。在方法开发中总共包括 27 种类固醇,以确保方法的特异性。验证后,该方法适用于 11 种类固醇的定量分析:E2(6.7 pM-13 nM)、E1(1.3 pM-6.6 nM)、T(3.3 pM-13 nM)、A4(13 pM-33 nM)、17OHP5(32 pM-65 nM)、17OHP4(33 pM-13 nM)、F(33 pM-133 nM)、E(13 pM-130 nM)、B(33 pM-134 nM)、S(13 pM-129 nM)和 A(32 pM-32 nM)。此外,还可以半定量分析 DHEA(333 pM-32 nM)、P4(13 pM-13 nM)和 21OHP4(13 pM-13 nM)。